Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 503 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 503 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $61.87 on Wednesday. The firm has a market cap of $7.64 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company’s 50 day moving average is $59.34 and its 200-day moving average is $54.84. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the subject of a number of research analyst reports. Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HALO. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $60,054,000. Capital World Investors purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $35,773,000. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after acquiring an additional 581,475 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock worth $39,750,000 after purchasing an additional 524,802 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Halozyme Therapeutics in the 4th quarter valued at $21,838,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.